These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 19432122)

  • 1. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. Treatment with bisphosphonates for cancer-induced bone disease].
    Abe M
    Clin Calcium; 2009 Jan; 19(1):55-62. PubMed ID: 19122265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical management update: multiple myeloma.
    Stoopler ET; Vogl DT; Stadtmauer EA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May; 103(5):599-609. PubMed ID: 17291793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Supportive care in multiple myeloma for continuing anti-myeloma therapies].
    Shibayama H
    Rinsho Ketsueki; 2014 Oct; 55(10):1999-2004. PubMed ID: 25297765
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bisphosphonates for myeloma patients].
    Miwa A
    Nihon Rinsho; 2007 Dec; 65(12):2315-37. PubMed ID: 18069279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
    Kraj M; Pogłód R; Maj S; Owczarska K
    Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R; Wilson T; Grbic JT
    Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 12. Complication related to bisphosphonate therapy: osteonecrosis of the jaw.
    Lee J
    J Infus Nurs; 2009; 32(6):330-5. PubMed ID: 19918142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC
    Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery.
    Chaudhry AN; Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2007 May; 19(2):199-206, vi. PubMed ID: 18088878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
    Timurağaoğlu A; Ozkaynak C; Tuzuner S; Bostan F; Undar L
    Acta Haematol; 2007; 118(4):203-4. PubMed ID: 17992010
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma.
    Altundag K; Altundag O; Gundeslioglu O
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15728824
    [No Abstract]   [Full Text] [Related]  

  • 19. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
    Sarasquete ME; González M; San Miguel JF; García-Sanz R
    Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
    Favia G; Pilolli GP; Maiorano E
    J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.